Research programme: nitric oxide synthase gene therapy - Cardion/Boehringer Ingelheim
Latest Information Update: 02 Jul 2007
At a glance
- Originator Boehringer Ingelheim
- Class Cell therapies; Gene therapies
- Mechanism of Action Nitric oxide synthase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Vascular disorders
Most Recent Events
- 14 Jun 2001 New profile
- 14 Jun 2001 Preclinical development for Vascular disorders in Austria (Unknown route)